Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology
Nifosi Antonio Fabrizio, Zuccarello Mariateresa, Nifosi Lorenzo, Saus Vanessa Hervas, Nifosi Gianfilippo,
소속 상세정보
( Nifosi Antonio Fabrizio ) - Dental Surgeon, Forli
( Zuccarello Mariateresa ) - University of Catania Department of Medicine
( Nifosi Lorenzo ) - European University of Valencia Department of Dentistry
( Saus Vanessa Hervas ) - European University of Valencia Department of Dental Hygiene
( Nifosi Gianfilippo ) - Brugmann University Hospital Center Department of Internal Medicine Hemato-Oncology Clinic
Abstract
Osteonecrosis of the jaw (ONJ) is a well-known pathological condition in oncology derived from the use of bisphosphonates (BPs) and denosumab. Many molecular and immunological targets have been introduced for daily use in cancer treatment in recent years; consequently, new cases of ONJ have been reported in association with these drugs, especially if administered with BPs and denosumab. When the drugs are administered alone, ONJ is rarely seen. The objective of our study was to analyze the recent literature relative to the association of ONJ with these new drugs highlighting the pathogenic, clinical and therapeutic aspects. The close collaboration between maxillofacial surgeon, oncologist, dentist, and dental hygienist remains the most important aspect for the prevention, prompt recognition, and treatment of this pathology.
키워드
Bone; Infection; Oral manifestations; Immunomodulation; Angiogenesis modulators
원문 및 링크아웃 정보
등재저널 정보